The World Health Organisation has confirmed a fresh outbreak of Ebola virus disease in the eastern Democratic Republic of Congo, with at least 80 fatalities reported in the past fortnight. The epicentre, near the city of Beni in North Kivu province, is a region still reeling from the 2018-2020 epidemic that claimed over 2,200 lives. Genetic sequencing suggests this strain shares 99.7% homology with the Zaire ebolavirus species targeted by the Ervebo vaccine. Yet rural immunisation rates here hover at 62%, leaving critical reservoirs of susceptibility.
The outbreak's velocity is alarming. In the first week of recognised transmission, 34 cases emerged across three health zones. Now the case fatality rate stands at 78%, a figure that grimly mirrors the pre-vaccine era. But there is reason for calibrated hope. The WHO has dispatched 7,500 doses of the recombinant vesicular stomatitis virus vaccine from its Geneva stockpile, with an additional 20,000 doses requested from the Gavi alliance. Mobile cold-chain units are being airlifted to Beni, though the terrain remains hostile. Militia activity by the Allied Democratic Forces has forced two vaccination teams to suspend operations this week.
Dr. Mike Ryan, Executive Director of the WHO Health Emergencies Programme, acknowledged the challenge during a press conference earlier today. "We are confronting two existing conditions: a high case load in a conflict zone and a population with waning vaccine confidence after multiple Ebola rings. But the science is clear: ring vaccination with Ervebo reduces transmission by 97.1% when implemented within 72 hours of case confirmation. We have the tools. We need the access."
The outbreak is part of a broader pattern. Since the discovery of Ebola in 1976, 90% of outbreaks have originated in the Congo Basin. Zaire ebolavirus persists in bat reservoirs, and deforestation rates in North Kivu have risen 34% since 2015, driving human-wildlife contact. Climate models suggest that by 2040, the average temperature in this region will increase by 1.8 degrees Celsius, expanding the viable habitat for fruit bats by 23%. We are witnessing not just a medical crisis but an ecological harbinger.
Rapid containment is possible but fragile. The current epidemic curve is roughly exponential, with a doubling time of 5.3 days. If transmission is not interrupted within the next two weeks, models project a worst-case scenario of 3,000 cases. The WHO has established an air bridge from Goma to Beni, but fuel shortages in the eastern DRC are delaying sample transport to the National Institute for Biomedical Research in Kinshasa. Turnaround times for RT-PCR tests have stretched to 18 hours, up from the target of 4 hours.
There are successes. In the Manguredjipa health zone, where the first case was recorded on 12 March, all 217 identified contacts have been vaccinated. No secondary cases have emerged. But in the city of Beni, population 600,000, contact tracing is incomplete. Community resistance persists, fuelled by misinformation that the vaccine causes infertility. Local radio stations are broadcasting messages from Congolese survivors who received the vaccine in 2019, none of whom have reported side effects.
For the global community, this is a familiar inflection point. The 2014 West African epidemic cost $2.8 billion and 11,325 lives before it ended. That toll could have been halved had the International Health Regulations been activated two weeks earlier. Today, the DRC government has declared a "high alert" but not yet an international public health emergency. The WHO Emergency Committee will convene by video call on Thursday to assess whether the situation meets that threshold.
In the interim, the laws of virology proceed with cold indifference. Each unbroken chain of transmission is a lottery draw for mutation. We have the serum. We lack the stillness to administer it.
